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General introduction 
Several types of hypoglycemic medication are currently given to patients with type 2 
diabetes mellitus. The applications presently available include insulin preparations and 
drugs for the improvement of insulin resistance, the promotion of insulin secretion and/or 
the suppression of postprandial hyperglycemia. Agents targeting incretin, a gastrointestinal 
hormone secreted by the stimulation of nutrients passing through the small intestinal lumen, 
have been a focus of attention in recent years based on the differences in their active 
mechanisms from those of other medications. While those methods established more precise 
treatment according to the causal factors, they have some disadvantages such as exorbitant 
costs, or adverse effects including gastrointestinal side effects and hypoglycemia (Nathan et 
al. 2009). It is due to these drawbacks that concomitant lifestyle interventions are needed, 
along with the development of other pharmaceutical cures. 
Blood glucose level is come out as a consequence of the amount of glucose moved into 
blood stream and that disappeared from blood stream. Glucose absorption in small intestine, 
particularly in jejunum, depends on the activities of two types of glucose transporter; 
sodium-dependent glucose cotransporter 1 (SGLT1) and glucose transporter (GLUT) 2. 
Glucose transfer from lumen side to the epithelial cell is brought about by active transport 
through SGLT1, while that from the epithelial cell to hepatic portal vein is by passive 
diffusion through GLUT2. GLUT2 is known not to require insulin stimulation for its 
function, and it is also reported that the passive diffusion through GLUT2 is a minor route 
in the process of small-intestinal glucose absorption (Krehbiel et al. 1996). These facts are 
thought to indicate that the amount of glucose transferred into blood stream in normal 
condition, is resulted from the efficiency of glucose transfer into the epithelial cells via 
SGLT1. Glucose in blood stream is cleared largely accompanied by the glucose uptake into 
skeletal muscle and adipose tissue, where insulin stimulates the translocation of GLUT4 
from inside of the cell onto the plasma membrane. In case of oral glucose administration, it 
results in a larger volume of insulin secretion than intravenous glucose injection. It is 
predominantly thought to be due to the enhancement of postprandial insulin secretion by 
incretin. This response has been called the incretin , which is exerted via different 
pathway from that of basic insulin secretion. Previous study revealed that incretin effect 
accounts for 50-70% of the total insulin secretion (Baggio and Drucker 2007). 
Maintenance of normoglycemia has a close relationship with an interaction between 
insulin and so-called stress-induced hormones ; catecholamines (norepinephrine and 
epinephrine), glucagon and glucocorticoids. Secretions in those hormones are 
conventionally adjusted depending on the feeding condition of the individual, while 
excessive external stress results in hyperresponsiveness of the two main axes; the 
sympathetic-adrenal medullary (SAM) system and the hypothalamic pituitary
adrenocortical (HPA) axis  The 
epinephrine-induced increase in plasma glucose is thought to be brought about by enhanced 
output of hepatic glucose in the fed condition, and attenuated glucose clearance (Issekutz 
and Allen 1972; Deibert and DeFronzo 1980). It has been demonstrated that glucagon is 
involved in glucose intolerance by facilitating hepatic glycogenolysis in the fed condition 
and gluconeogenesis in the fasted condition (Gastaldelli et al. 2000). Glucocorticoids are 
also known to promote glucose intolerance, with its effect in opposition to insulin action 
(Lambillotte et al. 1997; Andrews and Walker 1999). The secretion of epinephrine is 
considered to be resulted from the heightened stimulation of SAM system, while that of 
glucocorticoids is from HPA axis. Transient hyperglycemia via stress is an outcome of 
those responses, becoming an aggravating or crucial risk factor for type 2 diabetes mellitus. 
Lactoferrin (Lf) is a glycoprotein found in various mammalian body fluids, including 
blood, tears, saliva, and bile, and is especially abundant in milk (Masson et al. 1966; Baker 
1994). The potential of Lf has been evidenced by its physiologically pleiotropic properties, 
as represented by biophylactic responses such as anti-inflammatory and anti-cancer effects 
(Tsuda et al. 2000; Ishikado et al. 2005). The fact that Lf receptors are expressed in many 
organs also supports that multifunctionality, and introduces the possibility of 
as-yet-unknown influences (Suzuki et al. 2005). In recent years, interests have also been 
developed in the involvement of Lf in metabolic reactions. Lf supplementation improves 
lipid metabolism associated with reductions in the contents of hepatic cholesterol and 
triacylglycerol, accompanied by a suppressive effect on fat accumulation in the 
mesenterium and liver in mice (Takeuchi et al. 2004; Morishita et al. 2013).    
Moreno-Navarrete et al. (2009) have shown the direct relevance of Lf for diabetes 
mellitus: namely, the Lf concentration in blood is positively correlated to insulin sensitivity, 
and negatively to blood glucose levels in humans with altered glucose tolerance. 
Furthermore, it has been demonstrated a direct interaction of Lf with the active site of 
dipeptidyl peptidase IV (DPP-IV), an endogenously existing enzyme known to involve in 
incretin degradation and activity, indicating a potential of Lf for incretin preservation 
(Aroor et al. 2013; Nongonierma and FitzGerald 2014). Recent studies have also shown a 
close relationship between Lf and stress; Lf exerts its anxiolytic and analgesic effects 
accompanied by an increase in nitric oxide production or activation of the -opioid system  
(Takeuchi et al. 2003; Kamemori et al. 2004; Tsuchiya et al. 2006), and immobilization- 
stress-induced modification of the immune response is normalized by Lf via its 
anti-inflammatory effect or cytokine regulatory action (Zimecki et al. 2005). These facts 
may suggest the advantage of Lf for the correction of glucose metabolism and diabetic care, 
whereas it is still unknown whether Lf treatment can actually influence glucose tolerance in 
a normal or stressed individual. 
Based on those backgrounds, the present study aims to investigate whether treatment 
with bovine Lf (bLf) induces any changes in blood glucose regulation in normal rats and 
those under stress condition. In non-stress condition, oral glucose tolerance test (OGTT) 
and intravenous glucose tolerance test (IVGTT) were performed, in order to examine the 
effects of Lf on comprehensive glucose kinetics, including glucose clearance and absorption. 
In addition, the glucose absorption in small intestine and the influence of Lf treatment on it 
were estimated by conducting an in vitro study using the everted sac method. In stress 
condition, OGTT combined with restraint stress (RS) was performed for the investigation 
whether the treatment of Lf involves in stress-induced hyperglycemia and parameters. 
Chapter 1 
Effects of lactoferrin on blood glucose regulation and glucose 
absorption in the small intestine in normal rats 
Introduction 
The extent of alteration in glucose tolerance has been compartmentalized by fasting 
blood glucose level. OGTT has been a simple and useful test, in which temporal change in 
blood glucose level is observed after a certain amount of oral glucose administration 
(Andrikopoulos et al. 2008; Bartoli et al. 2011). OGTT enables to evaluate comprehensive 
glucose tolerance and insulinotropic response, while this test itself does not clearly 
represent the situation in the glucose absorption in small intestine. In contrast, IVGTT has 
been helpful in assessing glucose clearance after exogenous glucose delivery to blood 
circulation. That is to say, IVGTT allows indirect determination of the glucose tolerance for 
a certain volume of glucose injected. 
Responses to oral and intravenous glucose administration are different, and that is 
mainly caused by enhanced insulin secretion through incretin action (incretin effect). The 
effect is attributed to two types of incretin: glucose-dependent insulinotropic polypeptide 
(GIP) from K cells in the upper small intestine and glucagon-like peptide-1 (GLP-1) from L 
cells in the lower small intestine. Recent numerous studies have shown the strong 
relationship between incretin effect and glucose homeostasis; namely the promotion of 
sensitivity and the 
reduction of gastric emptying (Drucker 2006; Marathe et al. 2013). 
This chapter deals with the examination whether treatment with bovine Lf (bLf) causes 
any changes in blood glucose regulation, including plasma glucose, insulin or incretin 
secretion. Two types of glucose tolerance test, oral glucose tolerance test (OGTT) and 
intravenous glucose tolerance test (IVGTT), were conducted to assess the influence of Lf on 
blood glucose and insulin kinetics in relation to incretin effects. In addition, the effect of Lf 
on the efficiency of glucose absorption in the small intestine was determined by performing 
an experiment with the everted sac method using a piece of the jejunum. 
Materials and methods 
Materials
BLf, and aprotinin from a bovine lung were purchased from Wako Chemical Co., Ltd. 
(Osaka, Japan). The purity of bLf was more than 95.0% with a 0.005-0.035% iron 
saturation level, as determined by HPLC analysis, and neither LPS contamination nor other 
poisonings were reported from the bLf. Isoflurane was purchased from Intervet Inc. (Tokyo, 
Japan). The titanium vascular access port (SWIRL-MIN), dedicated 25-gauge needle and 
3-Fr polyurethane catheter were purchased from Primetech Co. (Tokyo, Japan). Urethane 
was purchased from Sigma-Aldrich (St.Louis, MO, USA). Sodium pentobarbital 
(Somnopentyl) was purchased from Kyoritsu Pharmaceutical Co., Ltd. (Tokyo, Japan). A 
3-Fr polyvinyl chloride catheter (atom nutrition catheter) was purchased from Atom 
Medical Co. (Tokyo, Japan). A 4-Fr polyethylene tube (Hibiki) was purchased from Kunii 
Co. (Tokyo, Japan). A tube containing ethylenediaminetetraacetic acid (EDTA-2K) was 
purchased from FUJIFILM Medical Co., Ltd. (Tokyo, Japan). 
Animals
All experimental protocols in this study were approved by the Animal Research 
Committee of Tottori University (approval numbers: 13-T-15 and 15-T-7). Male Wistar rats 
were obtained at 5 and 7 weeks of age from the Institute for Animal Reproduction (Ibaraki, 
Japan). The former were used for the experiment of glucose absorption; the latter for the 
glucose tolerance tests. The rats were acclimatized to their surroundings for at least one 
week before the experiments. The animal room was controlled with a 12/12 hr light/dark 
cycle (lights on 7:00-19:00) at an ambient temperature of 24 ± 1 °C. The rats were housed 
in plastic cages, with at most three rats per cage, and were allowed free access to water and 
standard chow (CE-2; Nihon Clea, Tokyo, Japan). The standard chow contains 24.9% 
protein, 4.6% fat, 4.5% fiber, 6.6% ash, 51.0% nitrogen free extract, and consists of 3.45 
kcal/g. All experiments were conducted after overnight (16 hr) fasting.  
Surgical operation for OGTT 
Prior to OGTT, rats were fully anesthetiz
implanted with a vascular access port on their dorsal region, as previously described 
(Higuchi et al. 2013). Subsequently, a 3-Fr polyurethane catheter connected to the titanium 
vascular access port was inserted into the exposed right external jugular vein. These 
approaches enabled me to obtain large volume of blood with less hemolysis. The catheter 
was prefilled and kept locked with heparin-added physiological saline by flushing the 
solution twice a day. OGTT was performed after 3-days of recovery from the operation.  
Surgical operation for IVGTT 
A series of surgical procedures involving in IVGTT was followed by reference to the 
protocol, described by Frangioudakis et al. (2007). Rats were anesthetized with 1 g/kg 
urethane (s.c.) and 6.48 mg/rat sodium pentobarbital (s.c.). A 3-Fr polyvinyl chloride 
catheter, as a cannula for blood collection, was inserted into the exposed right external 
jugular vein. Until the end of IVGTT, the catheter was prefilled and kept locked with 
heparin-added physiological saline. The solution was flushed after blood collection in 
volumes equal to the collected blood. In addition, a 4-Fr polyethylene tube with 2.5-cm 
length was subsequently placed in the trachea to keep the airway smooth.
OGTT 
The rats that had been operated upon were divided into four groups: group 1 received 
10 ml/kg of saline orally with saline at a dose of 1 ml/kg intraperitoneally; group 2 received 
10 ml/kg of saline orally with bLf at 100 mg/kg intraperitoneally; group 3 received 2 g/kg 
of glucose orally with saline at 1 ml/kg intraperitoneally; and group 4 received 2 g/kg of 
glucose orally with bLf at 100 mg/kg intraperitoneally. With oral saline administration, the 
effect of bLf on the endogenous glycemic change was assessed. The rats received the oral 
administration at 30 min after the intraperitoneal injection of saline or bLf. Blood samples 
were collected before the oral administration (0), and at 15, 30, 60, 90, 120, and 180 min 
after the oral administration. The volume of blood collected at each time point was 0.1 ml in 
groups 1 and 2, while in groups 3 and 4, it was 0.5 ml up to the 60 min point; after that, it 
was 0.1 ml. Twenty microliters of each obtained blood sample was used to measure plasma 
glucose just after the blood collection. The remainders of the blood, collected at every time 
point in group 1 and 2, and that up to the 60 min point in group 3 and 4, were transferred 
into an ethylenediaminetetraacetic-acid (EDTA)-containing tube (FUJIFILM Medical Co., 
Ltd., Tokyo, Japan) with aprotinin (final concentration, 500 KIU/mL, Wako Chemical Co., 
Ltd., Osaka, Japan), and centrifuged (5,600 × g, 5 min, 4 °C). All samples were stored at 
-80 °C until measurement for levels of insulin in groups 1 and 2; insulin, GIP and GLP-1 in 
groups 3 and 4, respectively. 
IVGTT
IVGTT was conducted to examine the direct influence of bLf on glucose clearance, 
discounting the factor of glucose absorption from the small intestine. Under continuous 
anesthesia of urethane and pentobarbital, the operated rats were intraperitoneally injected 
with saline (1 ml/kg) or bLf (100 mg/kg). 30 min after the injection, they were given an 
intravenous administration of glucose (1 g/kg) into the caudal vein. Blood samples were 
collected before the intravenous administration of glucose (0) and again at 5, 10, 20, 40, 60, 
120 min after the intravenous administration. The volume of blood collected at each time 
point was 0.2 ml. The obtained blood samples were processed experimentally using the 
same protocol as for OGTT section, and were used for the measurement of plasma glucose 
and insulin. 
Estimation of the glucose absorption across the everted sac of the small intestine 
The composition of Krebs-Henseleit buffer used in this experiment was as follows: 119 
mM NaCl, 21 mM NaHCO3, 0.6 mM KH2PO4, 2.4 mM K2HPO4, 1.2 mM CaCl2, 1.2 mM 
MgCl2, 6.0 mM L-glutamine and 15 mM D-glucose, as previously described with some 
modifications (Ishikawa et al. 2007; Han et al. 2013). Rats were sacrificed under sodium 
pentobarbital anesthesia (100 mg/kg, i.p.) at 1 hr after intraperitoneal injection of saline (1 
ml/kg, control) or bLf (100 mg/kg). An everted sac was made using the piece of jejunum 
and filled with 0.25 ml of Krebs buffer (Wilson and Wiseman 1954). The sac was incubated 
for 1 hr at 37 °C in a 50-ml flask containing 30 ml of Krebs buffer. Sample solutions were 
collected from outside (mucosal side) and inside (serosal side) the sac, and glucose 
concentrations were analyzed before (Mb, Sb) and after (Ma, Sa) the incubation, respectively. 
In addition, the sac weight was measured before (Wb) and after (Wa) collection of the serosal 
solution. The value of Wb-Wa (mg) was treated as the volume of the serosal solution after the 
incubation (µl). These parameters were used to calculate the total amount of glucose 
absorbed into the sac (TA) according to the following equation: 
TA (mg/g intestinal tissue) =[Sa (mg/dL) {Wb-Wa (µl)} 10-5 Mb (mg/dL) 0.25 (ml) 10-2] 
/Wa (mg) 103
Analysis of biochemical parameters 
Plasma glucose was measured by a portable electrode-type blood glucose meter 
(ANTSENSE III; Horiba, Ltd., Kyoto, Japan). Plasma insulin was determined by the 
enzyme immunoassay method using an ELISA kit (AKRIN-010T; Shibayagi Co., Ltd., 
Gunma, Japan). The total GIP level in plasma was measured using an ELISA kit 
(EZRMGIP-55K; Millipore Corp., Billerica, MA, USA), while total GLP-1 was measured 
with an EIA kit (YK160; Yanaihara Institute Inc., Shizuoka, Japan). The glucose 
concentration in the glucose absorption experiment was estimated using an enzymatic assay 
kit (Glucose CII-test WAKO; Wako Pure Chemicals, Osaka, Japan). 
Statistical analysis 
Data are represented as means ± SEM. Differences between the glucose concentrations 
of the mucosal and serosal sides of the everted sac, and those between the amounts of 
absorbed glucose into the sac in the bLf-treated group and the control group were 
statistically investigated using two-way ANOVA, followed by  post hoc test. In 
other experiments, the differences between the bLf-treated group and the control group 
t-test (GraphPad Prism version 6.0 for Windows; GraphPad 
Software Inc., La Jolla, CA, USA), and the score variation within a group was compared by 
a Univariate approach with a division model (JMP; SAS Institute Inc., Cary, NC, USA). 
Statistical significance was accepted at a probability (P) < 0.05. 
Results 
Changes in plasma glucose, insulin, total GIP and GLP-1 in OGTT 
As can be seen in Fig. 1A, plasma glucose varied in the range of about 25 mg/dL after 
the oral saline administration in both group. Within both groups, no significant changes 
were observed at each time point from basal level of plasma glucose. Although there were 
no significant differences in plasma glucose at each time point between the two groups, 
plasma glucose tended to be decreased 90 min after the oral saline administration. The Area 
Under the Curve (AUC) from 0 to 180 min also did not differ between the two groups 
(20,707 ± 1245 mg/dL × 3 hr in group 1 and 18,975 ± 1091 mg/dL × 3 hr in group 2). 
Similarly to the changes in plasma glucose, plasma insulin did not significantly 
changed at each time point from basal level (Fig. 1B). There were also no significant 
differences in plasma insulin at each time point between the two groups, while group 2 
showed a trend of higher levels of plasma insulin at and after 60 min from the oral saline 
administration, The Area Under the Curve (AUC) from 0 to 180 min also tended to be 
increased in the group 2 (47.2 ± 30.7 ng/mL × 3 hr in group 1 and 108.4 ± 41.6 ng/mL × 3 
hr in group 2). 
In OGTT, plasma glucose was lower at 0 min in group 4 (P = 0.046) (Fig. 1A). In both 
groups, plasma glucose immediately increased and reached a peak at 15 min after oral 
glucose administration (bLf: P < 0.05, control: P < 0.05). In group 3, the increment of
plasma glucose appeared to be sustained from the peak at 15 min to 60 min. In group 4, 
meanwhile, a tendency of mild decline in plasma glucose was observed in the same time 
period, and a significant reduction in plasma glucose was found at 180 min (P < 0.05). The 
AUC for plasma glucose tended to be lower in group 4 than in group 3 (29,082 ± 969 
mg/dL × 3 hr in group 3 and 27,543 ± 564 mg/dL × 3 hr in group 4, respectively).  
Plasma insulin was also immediately increased and reached a peak at 15 min after oral 
glucose administration in both groups (P < 0.05, resprectively, Fig. 1B). In group 3, plasma 
insulin gradually decreased after the peak to 120 min, and then plateaued until 180 min. In 
group 4, plasma insulin tended to remain elevated even after the peak, up to 90 min, and 
then showed plateauing values. At 30 min, the increasing width of insulin from 0 min was 
significantly larger in group 4 than in group 3 (group 3: 0.80 ± 0.072 ng/mL, group 4: 1.44 
± 0.108 ng/mL, P < 0.05). The AUC for plasma insulin also tended to increase in group 4, 
compared with that in group 3 (195.3 ± 25.1 ng/mL × 3 hr in group 3 and 212.4 ± 28.9
ng/mL × 3 hr in group 4, respectively). 
Total GIP in plasma increased within 15 min after oral glucose administration in both 
groups (P < 0.05, respectively, Fig. 2A). The high concentration was sustained until 60 min 
in group 3, whereas the level in group 4 showed a tendency of gradual decrease and was 
lower at 60 min (P < 0.05). The AUC for total GIP also tended to decrease in group 4, 
compared with that in group 3 (7,527 ± 512 pg/mL × 1 hr in group 3 and 6,312 ± 757 pg/mL 
× 1 hr in group 4, respectively). 
In group 3, total GLP-1 in plasma tended to show a gradual increase, and was higher at 
30 min compared with that from 0 min in OGTT (P < 0.05, Fig. 2B). On the other hand, the 
level in group 4 showed an immediate increase at 15 min (P < 0.05). Nevertheless, the AUC 
for total GLP-1 was almost same between the two groups (329.9 ± 11.5 ng/mL × 1 hr in 
group 3 and 331.3 ± 25.1 ng/mL × 1 hr in group 4, respectively). 
Changes in plasma glucose and insulin in IVGTT 
In IVGTT, plasma glucose reached a peak just after the injection of glucose (P < 0.05, 
respectively), rapidly decreased after the peak, and then continued to be flat after 40 min in 
both groups (Fig. 3A). At each time point, no significant difference was observed in plasma 
glucose between the two groups. The AUCs for plasma glucose in the bLf and the control 
groups were nearly the same (29,805 ± 2360 mg/dL × 2 hr in the control group and 29,077 
± 2149 mg/dL × 2 hr in the bLf group, respectively).  
Plasma insulin showed a similar transition to that of plasma glucose (P < 0.05, 
respectively, Fig. 3B). Although there was no significant difference in plasma insulin at any 
time point between the two groups, the bLf-treated group yielded a sustained increase in 
plasma insulin, which differed significantly from that at 0 min (P < 0.05). The AUC for 
plasma insulin did not also differ between the two groups (252 ± 17.8 ng/mL × 2 hr in the 
control group and 296 ± 26.6 ng/mL × 2 hr in the bLf group, respectively). 
Alteration in the glucose absorption in the everted sac of jejunum 
Fig. 4A shows the alteration in the glucose concentration inside and outside the everted 
sac of jejunum piece through incubation. Two-way ANOVA revealed significant effects of 
incubation (F1, 19 = 126.7, P < 0.01) and bLf treatment (F1, 19 = 8.333, P = 0.020) on the 
glucose concentration in the mucosal side of the sac: the incubation for 1hr and the bLf 
treatment resulted in significantly less glucose concentration on the mucosal side of the sac 
compared to saline, respectively. Significant effects were also noted in the serosal side 
(incubation: F1, 19 = 34.90, P < 0.01, bLf treatment: F1, 19 = 5.852, P = 0.042): the incubation 
for 1hr and the bLf treatment resulted in significantly more glucose concentration on the 
serosal side of the sac compared to saline, respectively. An interaction between incubation 
and bLf treatment was observed in the serosal side (F1, 19 = 6.791, P = 0.031), but not in the 
mucosal side (F1, 19 = 5.039, P = 0.055): the bLf treatment significantly enhanced an 
increase of glucose concentration in the serosal side of the sac, which was resulted from the 
incubation for 1hr, but not in that in the mucosal side of the sac.  
Significant effects on the calculated amount of glucose absorbed into the serosal side 
were found for incubation (F1, 19 = 72.51, P < 0.01) and bLf treatment (F1, 19 = 6.037, P = 
0.040): the incubation for 1hr and the bLf treatment resulted in significantly more glucose 
amount in the sac compared to saline, respectively (Fig. 4B). An interaction between 
incubation and bLf treatment was seen (F1, 19 = 9.186, P = 0.016): the bLf treatment 
significantly enhanced an increase of glucose amount in the sac, which was resulted from 
the incubation for 1hr. In the bLf group, the amount of glucose absorption after incubation 
was 1.7-fold that in the control group (6.1 ± 0.89 mg/dL in the control group and 10.6 ± 
1.39 mg/dL in the bLf group).   
Discussion 
In this study, OGTT measured the effect of Lf on the movement of glucose from the 
intestine into the blood, combined with the movement of glucose out of the blood, including 
incretin effect. On the other hand, IVGTT measured the effect of Lf on the movement of 
glucose out of the blood itself. The obtained results revealed the potential of Lf for blood 
glucose regulation as follows: Lf can decrease blood glucose in relation to the enhancement 
of insulin secretion by the incretin effect, despite the fact that Lf promotes glucose 
absorption in the small intestine. To my knowledge, this is the first study to investigate the 
effects of direct application of Lf on the whole glucose metabolism. The present findings 
may open up new possibilities for the treatment of glucose intolerance. 
Moreno-Navarrete et al. (2009) have suggested that the lower circulating Lf 
concentration in the humans with impaired glucose tolerance is relevant to the decreased 
number of neutrophils (the origin of endogenous Lf secretion). They also indicated the 
cause may be associated with the degranulation of neutrophils by hyperglycemia (Stegenga 
et al. 2008). The results in IVGTT demonstrated that the Lf treatment retained slightly 
higher plasma insulin levels in case of intravenous glucose administration. Though the 
possibility of Lf as the stimulant for insulin secretion could not be denied completely based 
on this finding, Lf was shown to result in no significant change in plasma glucose itself, 
indicating that Lf yielded negligible effects on glucose disposition in blood circulation in 
IVGTT. These facts suggest that there is much truth in the interpretation that Lf does not 
facilitate normal pancreatic function, and the change in blood glucose itself does not 
activate the effects of Lf.  
The experiment on oral saline administration was conducted to investigate the direct 
effect of Lf on endogenous blood glucose. Although it resulted in no significant effects of 
Lf on endogenous blood glucose changes and insulin secretion, the trend of lower plasma 
glucose was observed in later stage after the oral saline administration in the bLf-treated 
group. This change may provide the possibility that Lf contributes to the factors 
progressively required on fasted condition such as glucose uptake into muscle or adipose 
tissue and subsequent energy production. However, a tendency of increased insulin 
secretion was also observed temporally consistent with the changes in plasma glucose. As 
far as I know, there has been no information about direct involvement of Lf in endogenous 
insulin secretion. This regard is considered to be open to further discussion. 
Based on this suggestion, Lf tended to decrease plasma glucose persistently after oral 
glucose administration, and significantly reduced the value closer to the basal level. These 
results are consistent with the trend for higher transition and the significantly larger 
increasing width of insulin at 30 min in the Lf-treated group in OGTT. The enhancement of 
the total GLP-1 level in plasma at 15 min in Lf-treated group corresponded to the above 
routed through Ca2+ influx by the closure of the KATP channel. On the other hand, the 
KATP-independent pathway of insulin secretion is closely related to the increased cAMP 
potentiation of insulin secretion by the incretin effect proceeds through this pathway. 
Accordingly, it seems reasonable to conclude that the rapidly augmented GLP-1 secretion 
contributed to the simultaneous enhancement of insulin secretion by Lf. Until recently, the 
question of whether Lf is tied with incretin secretion seemed to be unresolved. However, in 
the past several years, evidence has accumulated that whey containing Lf shows DPP-IV 
inhibitory action and exerts acute effects on incretin effect and glucose metabolism (Graf et 
al. 2011; Nongonierma and FitzGerald 2013). These findings do not negate the possibility 
that Lf plays a part in the preservation or direct acceleration of the incretin effect. In other 
words, Lf may be a useful candidate both to stimulate incretin secretion and to inhibit its 
degradation. 
Attention must be directed toward the finding that basal plasma glucose was increased 
in the control group, compared with the Lf-treated group in OGTT. Superficially regarded, 
it can be inferred that Lf ameliorated mild stress arising from the surgical operation or the 
manipulation during OGTT. In fact, Lf has anxiolytic and analgesic effects accompanied by 
an increase in nitric oxide production or activation of the µ-opioid system (Takeuchi et al. 
2003; Kanemori et al. 2004; Tsuchiya et al. 2006). These effects suggest that Lf can give 
rise to a reduction in stress hormone secretion, brought about by interrupting the signaling 
pathway of those hormones past the cerebral cortex. On the other hand, the result in OGTT 
showed a trend toward lower basal level of plasma insulin in Lf-treated group, seemingly 
conflict with higher plasma glucose at the same time point. This contradiction may be 
related to the previously reported fact that acute physical stress leads to hyperglycemia 
without affecting insulin secretion (Romeo et al. 2007). Although it is possible that the 
physical stress, accompanied by the surgical operation, might not be fully passed off after 
3days of recovery, that impact could be considered to be continued acutly or subacutely. In 
this regard, it raises the possibility that there was no close interaction between the basal 
levels of plasma glucose and insulin. 
Lf did not change the total GIP in plasma just after the oral glucose administration, but 
did significantly lower that at 60 min. Meanwhile, plasma insulin tended to be higher over 
the same period. These results appear to contradict the previously assumed association 
between both incretins and insulin secretion. According to previous research using K cell 
signaling-modified mice, the GIP response to orally administered glucose was depressed, 
while the glucose tolerance was not affected (Pedersen et al. 2013). This suggests that GIP 
makes only a slight contribution to glucose regulation, not only in individuals with impaired 
glucose tolerance, but also in normal individuals. The present finding that the plasma 
glucose-lowering effect and GIP secretion-lowering effect coexisted supports the above 
suggestion, and further strongly suggests that the immediate increase in GLP-1 secretion 
induced by Lf had an influence on blood glucose and insulin. 
From the results in Fig. 4A, it can be regarded that typical glucose transport through 
small-intestinal epithelial cells occurred in the glucose absorption experiment. In addition, 
Lf increased both the glucose concentration in the serosal side after incubation and the 
calculated amount of glucose absorption into the sac. It would be incorrect to conclude that 
Lf increased the expression of GLUT2 in small-intestinal epithelial cells, since Lf was 
intraperitoneally injected to rats only 1 hr before isolating the whole of the small intestine. 
However, the promotion of small-intestinal glucose absorption is not always associated with 
quantitative GLUT2 expression. One finding suggesting that Lf directly contributes to the 
enhancement of glucose transport into small-intestinal epithelial cells is that Lf alleviated 
the inhibition of glucose transport into absorptive enterocytes through SGLT1, by 
down-regulating the Ca2+ and cAMP signaling pathway (Talukder et al. 2014). Although the 
fact that glucose uptake into muscle and adipose tissue is through the enhancement of the 
translocation of GLUT4 to the plasma membrane triggered by insulin stimulation (Czech 
and Corvera 1999; Bryant et al. 2002), previous research has suggested that whey protein 
hydrolysate increases the translocation of GLUT4 to the plasma membrane in muscle tissue 
independently of insulin (Morato et al. 2013). With the consideration that the function of 
GLUT2 in the small intestine does not require insulin action, these findings may suggest 
that Lf augments the frequency of GLUT2 translocation to the surface of the plasma 
membrane of the epithelial cell, promoting glucose transfer to blood circulation. A detailed 
analysis of this possibility will be needed in future works. 
The glucose absorption experiment was performed using a part of jejunum, where L 
cells do not locate but K cells do. Given the total GIP-lowering effect of Lf, it seems quite 
possible that Lf caused the decrease in the amount of glucose within the jejunum space, 
leading to lower GIP secretory stimulation. It is probable that Lf does not simply influence 
the receptor responsiveness of both incretins, given the inverse results between GIP and 
GLP-1 in this study. Ikoma-Seki et al. (2015) recently proposed that Lf induces lipolysis 
associated with the activation of hormone-sensitive lipase and adenylate cyclase in adipose 
tissue. The former activation is caused by the promotion of the intracellular cAMP signaling 
pathway, the latter by the cAMP response element binding protein. As mentioned above, the 
enhancement of insulin secretion by the incretin effect also has a close relation to the cAMP 
concentration, which varies by the activation of adenylate cyclase after incretin binds to its 
receptor. There remains the possibility that Lf has a similar effect on the signaling pathway 
in the process of the insulin secretory promotion by the incretin effect, and that the change 
of GIP level in the early stage of OGTT is virtually cancelled out by the insulin signaling 
activation and decreased GIP secretory stimulation. 
In conclusion, it was found that Lf does contribute to the elevation of plasma insulin 
and the transient acceleration of GLP-1 secretion, possibly leading to the attenuation of 
hyperglycemia, even with the enhancement of glucose absorption in the small intestine.  
Fig. 1  Temporal change in plasma glucose and insulin following the oral administration of saline 
or glucose. The rats were intraperitoneally injected with saline (1 ml/kg) or bLf (100 mg/kg). 30 
min after the injection, they were given an oral administration of saline (10 ml/kg) or glucose (2 
g/kg). Each data point represents the mean ± SEM from 3 rats per group in case of oral saline 
administration, and 5-6 rats per group in case of oral glucose administration. (A) Changes in plasma 
glucose; (B) Changes in plasma insulin. Black triangle shows the time point of oral administration of 
saline or glucose. Dotted and Solid lines show the group of oral administration of saline and the 
group of oral administration of glucose, respectively. Open and filled circles show the group of 
intraperitoneal injection of saline and the group of intraperitoneal injection of bLf, respectively. 
*Significant difference from the value at 0 min in each group (based on a Univariate approach with a 
division model; P < 0.05). Significant difference from the value at the same time point between the 
t-test; P < 0.05). 







































Fig. 2  Temporal change in total GIP and GLP-1 in plasma following the oral administration of 
glucose. The rats were intraperitoneally injected with saline (1 ml/kg) or bLf (100 mg/kg). 30 
min after the injection, they were given an oral administration of glucose (2 g/kg). Each data 
point represents the mean ± SEM from 5 rats per group. (A) Changes in total GIP in plasma; (b) 
Changes in total GLP-1 in plasma. Black triangle shows the time point of oral administration of 
glucose (2 g/kg). Open and filled circles show the group of intraperitoneal injection of saline and the 
group of intraperitoneal injection of bLf, respectively. *Significant difference from the value at 0 
min in each group (based on a Univariate approach with a division model; P < 0.05). Significant 
t-test; P < 
0.05).























Fig. 3  Temporal change in plasma glucose and insulin following the intravenous injection of 
glucose. The rats were intraperitoneally injected with saline (1 ml/kg) or bLf (100 mg/kg). 30 
min after the injection, they were given an intravenous administration of glucose (1 g/kg) into the 
caudal vein. Each data point represents the mean ± SEM from 5 rats per group. (A) Changes in 
plasma glucose; (B) Changes in plasma insulin. Black triangle shows the time point of intravenous 
administration of glucose (1 g/kg). Open and filled circles show the group of intraperitoneal 
injection of saline and the group of intraperitoneal injection of bLf, respectively. *Significant 
difference from the value at 0 min in each group (based on a Univariate approach with a division 
model; P < 0.05).  

































Fig. 4  Alteration in glucose absorption into an everted jejunum sac. The rats were 
intraperitoneally injected with saline (1 ml/kg) or bLf (100 mg/kg). 1 hr after the injection, they 
were sacrificed and the everted sacs were prepared. Each data point represents the mean ± SEM 
from 5 rats per group. (A) Glucose concentration outside (mucosal side) / inside (serosal side) the 
sac before and after the incubation. White and black squares show the glucose concentration before 
and after the incubation, respectively. (B) The amount of absorbed glucose into the sac per 1 g of 
jejunum tissue after the incubation. White and black squares show the amount of absorbed glucose 


























Effect of lactoferrin on blood glucose regulation in rats 
under stress condition 
Introduction 
Normoglycemia is maintained by an interaction between insulin and catecholamines 
(norepinephrine and epinephrine), glucagon and glucocorticoids. The stress-induced 
hormones are known to increase endogenous level of blood glucose, accompanied by the 
enhancement of hepatic glucose output, glucose intolerance or insulin resistance, and with 
relation to the changes of glycogenolysis in fed condition and that of gluconeogenesis in 
fasted condition. Secretions in those hormones are conventionally adjusted depending on 
the feeding condition of the individual, while exposure to physical stressors also affects 
those secretions both acutely and chronically.  
Restraint stress (RS) is a widely used method of the assessment of physical stress in 
rats. RS induces hyperglycemia accompanied by an increase in an adrenocorticotropic 
hormone, such as corticosterone (Giralt and Armario 1989; Tabata et al. 1998). Previous 
studies have shown that plasma glucose is not affected by the infusion of corticoid itself or 
by a subacutely repeated load of RS (24 hr) to rats, while acute RS (1 hr) induces 
hyperglycemia with increased plasma corticosterone (Torres et al. 2001). Therefore, it is 
believed that RS can be useful in evaluating the relationship between glucose homeostasis 
and the acute disorder in corticosterone-related pillar, namely the HPA axis. On the other 
hand, glucose endogenously synthesized by gluconeogenesis is known to account for >80 % 
of the total glucose, even after 4 hr fasting in rodents, and strengthens the causal 
relationship between decreased levels in plasma glucose and corticosterone (Burgess et al. 
2005; Kowalski and Bruce 2014). 
Based on the finding in Chapter 1 that Lf facilitates potential glucose regulation 
accompanied by the enhancement of the incretin effect, the present study aims to examine 
whether treatment with Lf induces any changes in glucose regulation in rats under RS. In 
this chapter, OGTT was performed to assess the influence of Lf on the blood glucose and 
insulin kinetics in the RS load. Stress-induced hormones, such as plasma corticosterone, 
epinephrine and glucagon, were also measured to estimate the impact of RS on those 
parameters. 
Materials and methods 
Materials
BLf, and aprotinin from a bovine lung were purchased from Wako Chemical Co., Ltd.. 
Isoflurane was purchased from Intervet Inc.. The titanium vascular access port 
(SWIRL-MIN), dedicated 25-gauge needle and 3-Fr polyurethane catheter were purchased 
from Primetech Co.. Urethane was purchased from Sigma-Aldrich. A tube containing 
EDTA-2K was purchased from FUJIFILM Medical Co., Ltd.. A dedicated wire restraint 
cage (KN-468) was purchased from Natsume Seisakusho Co., Ltd. (Tokyo, Japan).
Animals
All experimental protocols in this study were approved by the Animal Research 
Committee of Tottori University (approval numbers: 16-T-6). Male Wistar rats were 
obtained at 7 weeks of age from the Institute for Animal Reproduction. The rats were 
acclimatized to their surroundings for at least one week before the experiments. The animal 
room was controlled with a 12/12 hr light/dark cycle (lights on 7:00-19:00) at an ambient 
temperature of 24 ± 1 °C. The rats were housed in plastic cages, with at most three rats per 
cage, and were allowed free access to water and standard chow (CE-2). All experiments 
were conducted after overnight (16 hr) fasting.  
Surgical operation for OGTT 
implanted with a vascular access port on their dorsal region, as previously described 
(Higuchi et al. 2013). Subsequently, a 3-Fr polyurethane catheter connected to the titanium 
vascular access port was inserted into the exposed right external jugular vein. The catheter 
was prefilled and kept locked with heparin-added physiological saline by flushing the 
solution twice a day. OGTT was performed after 3-days of recovery from the operation.  
OGTT 
The rats that had been operated upon were divided into four groups: group 1 received 
10 ml/kg of saline orally with saline at a dose of 1 ml/kg intraperitoneally; group 2 received 
10 ml/kg of saline orally with bLf at 100 mg/kg intraperitoneally; group 3 received 2 g/kg 
of glucose orally with saline at 1 ml/kg intraperitoneally; and group 4 received 2 g/kg of 
glucose orally with bLf at 100 mg/kg intraperitoneally. With oral saline administration, the 
effect of bLf on the endogenous blood glucose change in the stressed condition and the 
impact of the RS itself on glycemic change were assessed. The rats received the oral 
administration at 30 min after the intraperitoneal injection, and then RS was applied for 60 
min. RS was applied to the rats by getting them into a dedicated wire restraint cage with 
reference to the method of Hirata et al. [10]. Blood samples were collected before the 
intraperitoneal injection (-30), before the oral administration (0), and at 30, 60, 90, 120, and 
180 min after the oral saline administration. The volume of blood collected at each time 
point was 0.1 ml in groups 1 and 2, while in groups 3 and 4, it was 0.5 ml at 0, 30, and 60 
-30, 90, 120 and 180 min. Twenty microliters of each obtained blood 
sample was used to measure plasma glucose just after the blood collection. The remainder 
of the blood, collected at 0, 30, 60 min, was transferred into an EDTA-containing tube with 
aprotinin (final concentration, 500 KIU/mL), and centrifuged (5,600 × g, 5 min, 4 °C). All 
samples were stored at -80 °C until measurement for levels of insulin and corticosterone in 
groups 1 and 2; insulin, corticosterone, epinephrine and glucagon in groups 3 and 4, 
respectively.  
Analysis of biochemical parameters 
Plasma glucose was measured by a portable electrode-type blood glucose meter 
(ANTSENSE III). Plasma insulin was determined by the enzyme immunoassay method 
using an ELISA kit (AKRIN-010T). The corticosterone level in plasma was measured using 
an ELISA kit (ENC-ERKR7004; Endocrine Technologies Inc., Newark, CA, USA), and 
epinephrine was measured with an ELISA kit (BA E-5100; LDN, Nordhorn, Germany). The 
glucagon level in plasma was measured using a competitive EIA kit (MK157; Takara Bio 
Inc., Shiga, Japan). 
Statistical analysis 
Data are represented as means ± SEM. The differences between the bLf-treated group 
t-test (GraphPad Prism version 6.0 for 
Windows), and the score variation within a group was compared by a univariate approach 
with a division model (JMP). Statistical significance was accepted at a probability (P) < 
0.05. 
Results 
Changes in plasma glucose and insulin following the oral administration of saline or 
glucose, and RS load 
As shown in Fig. 5A, plasma glucose varied in the range of about 30 mg/dL in groups 
1 and 2. Significant increases in plasma glucose were observed at 30, 60 and 90 min 
compared with the level at the time of oral administration (0 min) in group 1, while the 
level in group 2 tended to show a gradual increase in the same comparison. In both groups, 
plasma glucose was not significantly changed at 0 min from the level at the time of 
intraperitoneal administration (-30 min). The area under the curve (AUC) from 0 to 180 min 
was almost the same in groups 1 and 2 (22,341 ± 545 mg/dL × 3 hr in group 1 and 22,734 ± 
1315 mg/dL × 3 hr in group 2).
As for plasma insulin, in both groups, no significant change from basal level was 
observed at each time point during RS period (Fig. 5B). There were also no significant 
differences in the levels between the two groups. The AUC from 0 to 60 min was nearly the 
same in the two groups (37.9 ± 9.6 ng/mL × 1 hr in group 1 and 33.4 ± 5.7 ng/mL × 1 hr in 
group 2). 
In OGTT, plasma glucose entirely maintained a higher transition in group 3, compared 
with that in group 4 (Fig. 5A). The peak level of plasma glucose was observed immediately 
after the oral glucose administration in group 3 (30 min), and the level was sustained for at 
least 30 min. Meanwhile, a gradual increase in plasma glucose to its peak at 60 min was 
seen in group 4. Group 4 also exhibited significant decreases in plasma glucose at 0, 30, and 
180 min relative to each level in group 3. The AUC was also significantly lower in group 4 
than in group 3 (33,660 ± 935 mg/dL × 3 hr in group 3 and 27,798 ± 423 mg/dL × 3 hr in 
group 4). 
Groups 3 and 4 displayed a peak of plasma insulin at 30 min and significant increases 
at 30 and 60 min after the oral glucose administration (Fig. 5B). Meanwhile, there were no 
significant differences in the level of plasma insulin at each time point, and the AUCs for 
insulin were nearly the same in the two groups (101.9 ± 9.0 ng/mL × 1 hr in group 3 and 
101.1 ± 11.9 ng/mL × 1 hr in group 4). 
Changes in plasma corticosterone following the oral administration of saline or glucose, 
and RS load 
Significant increases in plasma corticosterone were seen at 30 and 60 min after the RS 
load within group 1, while there were no changes in the level within group 2 (Fig. 6). In 
addition, group 2 showed a significant decrease in the level at 30 min, and tended to lower 
the levels at 0 and 60 min. The AUC was significantly lowered in group 2 (10,937 ± 977 
ng/mL × 1 hr in group 1 and 7,758 ± 673 ng/mL × 1 hr in group 2).
In OGTT, the increment of plasma corticosterone was seen immediately after the RS 
load in group 3, and the level appeared to be sustained from the peak at 30 min to 60 min at 
least (Fig. 6). On the other hand, a mild increase in and the sustaining of the plasma 
corticosterone level were observed within group 4 after the RS load, and significant 
reductions in the level were found at 30 and 60 min. The AUC for plasma corticosterone 
was also significantly lower in group 4 than in group 3 (12,763 ± 755 ng/mL × 1 hr in group 
3 and 9,259 ± 365 ng/mL × 1 hr in group 4). 
Changes in plasma epinephrine and glucagon following the oral administration of glucose, 
and RS load 
Epinephrine in plasma tended to increase within 30 min after the RS load in group 3, 
whereas the level in group 4 showed a mild increment at the same time point (Fig. 7A). 
However, no significant difference was found in the AUC for epinephrine between the two 
groups (40,711 ± 10,148 pg/mL × 1 hr in group 3 and 36,652 ± 3,142 pg/mL × 1 hr in group 
4). The results in Fig. 7B showed that plasma glucagon remained at about the baseline level 
during the RS load within groups 3 and 4. The overall transition of the level was also very 
similar between the two groups, and there were no significant differences in the levels or the 
AUCs for glucagon between the groups (5,418 ± 503 pg/mL × 1 hr in group 3 and 5,143 ± 
624 pg/mL × 1 hr in group 4).
Discussion
In the present study, the RS load with oral saline administration resulted in the 
increment of plasma glucose within the group receiving an intraperitoneal saline injection. 
This result was in accord with previously reported studies, which showed the 
hyperglycemia induced by 30-60 min of acute RS (Torres et al. 2001; Romeo et al. 2007). 
Contrary to the increase in those levels found within the intraperitoneal-saline-injected 
group, no significant changes were observed in plasma glucose within the 
intraperitoneal-bLf-injected group. These differences were temporally consistent with the 
changes in plasma corticosterone, while plasma insulin was not affected by RS load. These 
finding may suggest that Lf has the potential to attenuate the hyperglycemic responses 
brought about by the increase of corticosterone secretion following the RS. It can also be 
concluded that the RS load acted as a sufficient stressor to elicit hyperglycemia even in 
OGTT. 
In OGTT, an initial rise in plasma glucose was found at 30-60 min after the oral 
glucose administration. This phase was overlapped by the RS period, and plasma 
corticosterone was significantly elevated in response to RS. It has been reported that acute 
RS (30 min) causes hyperglycemia without affecting plasma insulin in rats (Romeo et al. 
2007), indicating that the RS load adopted in the present study could also have no impact on 
endogenous insulin secretion. The data obtained in OGTT revealed no changes in plasma 
glucagon following the RS load, while a slight increase in plasma epinephrine was found at 
30 min after the RS load was started only in the case of intraperitoneal bLf injection. 
Although the latter result does not negate the possibility that bLf enhanced epinephrine 
secretion, the largely lowered corticosterone and plasma glucose levels during RS are 
assumed to indicate a lower contribution to hyperglycemia by epinephrine. However, these 
results appeared not to be consistent with the previous research, which showed that acute 
immobilization (60 min) causes hyperglycemia accompanied by increases in the secretion 
of all of the three stress-induced hormones in rats under the fed condition (Yamada et al. 
1993). The apparent contradiction in the secretary status of stress-induced hormones is 
considered to be brought about by the difference in stress severity between RS and 
immobilization. In addition, these facts lead to the possibility that the increment in plasma 
glucose, which was observed in the early stage in OGTT, was mainly associated with the 
actions yielded by increased corticosterone. 
The obtained results suggest that Lf suppresses the increment of plasma glucose that 
occurs as a result of the combination of oral glucose administration and acute RS load. 
Although the suppressive change in plasma glucose was consistent with the decrease in 
plasma corticosterone, Lf did not induce such changes in plasma epinephrine and glucagon 
during RS. These findings indicate that Lf may be involved in the hypoglycemic responses 
that occur under stress conditions, which can be attributed to the attenuated activation of the 
HPA axis rather than to that of the sympathetic nervous system. Southorn et al. (1990) have 
shown that insulin resistance caused by increased corticosterone is largely related to 
decreased insulin sensitivity. This finding is considered to support the result that Lf showed 
a hypoglycemic effect without affecting insulin secretion, and may suggest that Lf affects 
the improvement of corticosterone-related insulin resistance. 
Fig. 5  Temporal change in plasma glucose and insulin following the oral administration of saline 
or glucose, and RS. The rats were intraperitoneally injected with saline (1 ml/kg) or bLf (100 mg/kg). 
30 min after the injection, they were given an oral administration of saline (10 ml/kg) or glucose (2 
g/kg), and then RS was applied for 60 min. Each data point represents the mean ± SEM from 5 rats 
per group. (A) Changes in plasma glucose; (B) Changes in plasma insulin. White triangle shows the 
time point of intraperitoneal injection of saline or bLf. Black triangle shows the time point of oral 
administration of saline or glucose. Dotted and Solid lines show the group of oral administration of 
saline and the group of oral administration of glucose, respectively. Open and filled circles show the 
group of intraperitoneal injection of saline and the group of intraperitoneal injection of bLf, 
respectively. *Significant difference from the value at 0 min in each group (based on a Univariate 
approach with a division model; P < 0.05). Significant difference from the value at the same time 
t-test; P < 0.05).
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Fig. 6  Temporal change in plasma corticosterone following the oral administration of saline or 
glucose, and RS. The rats were intraperitoneally injected with saline (1 ml/kg) or bLf (100 mg/kg). 
30 min after the injection, they were given an oral administration of saline (10 ml/kg) or glucose (2 
g/kg), and then RS was applied for 60 min. Each data point represents the mean ± SEM from 5 rats 
per group. Black triangle shows the time point of oral administration of saline or glucose. Dotted and 
Solid lines show the group of oral administration of saline and the group of oral administration of 
glucose, respectively. Open and filled circles show the group of intraperitoneal injection of saline 
and the group of intraperitoneal injection of bLf, respectively. *Significant difference from the value 
at 0 min in each group (based on a Univariate approach with a division model; P < 0.05). 
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Fig. 7  Temporal change in plasma glucose, insulin and corticosterone following the oral administ- 
ration of glucose. Each data point represents the mean ± SEM from 5 rats per group. The rats were 
intraperitoneally injected with saline (1 ml/kg) or bLf (100 mg/kg). 30 min after the injection, they 
received the oral administration of glucose (2 g/kg), and then RS was applied for 60 min. (A) 
Changes in plasma glucose; (B) Changes in plasma insulin; (C) Changes in plasma corticoste- rone. 
White triangle shows the time point of the intraperitoneal injection of saline or bLf. Black triangle 
shows the time point of the oral administration of glucose. Open and black-filled circles show the 
group of intraperitoneal injection of saline and the group of intraperitoneal injection of bLf, 
respectively. *Significant difference from the value at 0 min in each group (based on a univariate 
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General Discussion 
LF is a glycoprotein found in various mammalian body fluids, and especially abundant 
in milk. Evidences of the physiological multifunctionality of Lf have been accumulated, as 
represented by biophylactic responses such as analgesia or anti-stress effect, and the 
recent interests have been focused on its involvement in metabolic reaction. However, the 
influence of Lf on blood glucose regulation still remains an open research problem. A major 
goal of this study has been to examine whether Lf affects glucose mechabolism in normal 
and stress condition. The effect of Lf on comprehensive glucose kinetics was investigated 
by performing OGTT and IVGTT, and that on small-intestinal glucose absorption was 
estimated by an in vitro study using the everted sac method. On the other hand, the 
involvement of Lf in the stress-induced hyperglycemia was assessed by conducting the 
OGTT, which is combined with RS.
I concluded that Lf acts as a temporal enhancer of GLP-1 secretion in L cell, 
accompanied by its exertion of the promotion of insulin secretion in normal condition. 
However, in the stress condition, the Lf treatment did never show any changes in insulin 
secretion in the RS period. Lf is known to promote the translocation of GLUT4 onto plasma 
membrane in muscle or adipose tissues independently on insulin action. From the 
observation that the hypoglycemic action by Lf was thought not to be accompanied by the 
requirement for the enhancement of insulin secretion, the above action, which related to the 
promotion of glucose uptake into peripheral tissues, may resulted in the lower transition of 
plasma glucose in the stress condition. Furthermore, those results are considered to indicate 
that RS cancelled out the enhancement of GLP-1 secretion brought about by Lf. The central 
role of GLP-1 in stress condition has been focused on in previous studies, as yet known that 
both HPA axis and sympathetic nervous system are primed with the activation of central 
GLP-1 receptor (Holt and Trapp 2016). In addition, the other study has revealed the 
possibility of stress to enhance the physiological action of GLP-1; namely that GLP-1 
neuron can be activated by a treatment with lithium chloride, lipopolysaccharide and 
cholecystokinin (Rinaman 1999). These findings are highly suggestive to explain that 
adaptive hypothalamic stress responses themselves results in hyperglycemic changes. On 
the other hand, restraint stress also affects the absorption of nutrients associated by changes 
in intestinal motility (Tsukada et al. 2002). In fact, glucocorticoids cause a decreased 
translocation of the intestinal GLUT2 and glucose absorption (Shepherd et al. 2004). As 
mentioned above, the secretion of incretin is followed by the nutrients stimulation on the 
specific cells, K cell and L cell, in the intestinal lumen. Based on the mechanism of GLP-1 
secretion, one reason for no changes in insulin secretion in the stress condition can be lower 
stimulation in L cell caused by the disorder of intestinal morphology, while the RS load 
might lead to the activation of GLP-1 receptor. 
Conclusion 
Lf has a potential to suppress hyperglycemia, accompanied by plasma insulin elevation 
via transiently accelerating GLP-1 secretion in normal condition, and that Lf even enhances 
glucose absorption from the small intestine. In stress condition, Lf suppresses the elevation 
of plasma glucose possibly accompanied by mediating HPA axis, not affecting SAM system 
or gluconeogenesis. These findings suggest that treatment by Lf might be useful as one 
method of decent glycemic control. 
Summary 
Firstly, the investigation whether lactoferrin (Lf) affects glycemic regulation of rats in 
normal condition was conducted. Focusing on the anti-stress effects of Lf, the influence of 
Lf on the glycemic changes, which was brought about by restraint stress (RS), was also 
evaluated. From carrying out the two experiments, I had the results as follows; 
1. In normal condition, bovine Lf (bLf) pretreatment (100 mg/kg) had no significant 
effect on plasma glucose or insulin after the intravenous injection of glucose. On the other 
hand, in case of the oral glucose administration (oral glucose tolerance test, OGTT), the bLf 
treatment tended to show lower plasma glucose at and after the 15-min peak than the 
control group, and decreased at 180 min. In addition, the change in plasma insulin from 0 to 
30 min was higher in the bLf group than in the control group.  
2. In normal condition, total plasma glucose-dependent insulinotropic polypeptide (GIP) 
was lowered at 60 min by the bLf treatment, while an immediate increase in total plasma 
glucagon-like peptide-1 (GLP-1) was observed within the bLf group undergoing the OGTT. 
3. The bLf pretreatment was associated with an increase in the amount of glucose 
absorbed into the everted jejunum sac. 
4. RS significantly raised plasma glucose, but the bLf pretreatment did not affect the level. 
In the stress condition, plasma glucose showed an overall lower transition in the bLf group 
in OGTT, and the levels at 30 and 180 min or the area under the curve (AUC) were 
significantly decreased. Although the bLf treatment suppressed an increase in plasma 
corticosterone during RS, the levels of plasma insulin, epinephrine and glucagon were not 
changed by the bLf treatment.  
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